Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN03885092
ISRCTN03885092
Completed
Phase 3

A randomised, double-blind controlled trial of mometosone furoate cream versus placebo to prevent radiation dermatitis of the breast and chest wall

ancashire Teaching Hospitals NHS Trust (UK)0 sites120 target enrollmentJuly 7, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsTopic: National Cancer Research NetworkSubtopic: Breast CancerDisease: BreastSigns and SymptomsRadiation dermatitis

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Topic: National Cancer Research Network
Sponsor
ancashire Teaching Hospitals NHS Trust (UK)
Enrollment
120
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

2014 Results article in https://doi.org/10.1016/j.ijrobp.2014.06.033 (added 24/01/2022)

Registry
who.int
Start Date
July 7, 2010
End Date
July 31, 2011
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ancashire Teaching Hospitals NHS Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Aged 18 years or over, either sex
  • •2\. Receiving 40 Gy 15 fractionated, 3 week radical radiotherapy to the breast or chest wall
  • •3\. Patient provides informed consent to participate in the study and completes follow up

Exclusion Criteria

  • •1\. Skin involvement of disease
  • •2\. Untreated bacterial, fungal or viral skin lesions
  • •3\. Inability to self administer creams

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Fulvestrant and vandetanib in advanced aromatase inhibitor resistant breast cancerMetastatic breast cancerCancer
ISRCTN13663157Velindre NHS Trust165
Completed
Phase 2
Evaluating the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapyRheumatoid arthritisMusculoskeletal DiseasesOther rheumatoid arthritis
ISRCTN67054656ChemoCentryx, Inc. (USA)150
Completed
Not Applicable
A double blind, randomised, placebo controlled, multicentre trial of Anti-Tumour Necrotising Factor alpha (Anti-TNFa) chimeric monoclonal antibody (infliximab, Remicade®) in combination with methotrexate in patients with very early inflammatory arthritisEarly inflammatory arthritisMusculoskeletal DiseasesArthritis
ISRCTN21272423Medical University of Vienna (Austria)89
Completed
Phase 1
A study of the effects of different doses of oliceridine on several brain functions and a pain test, in healthy volunteers, compared to morphineNot ApplicableEffects of oliceridine and morphine on neurocognition and pain in healthy participants
ISRCTN13308001Trevena, Inc.23
Completed
Not Applicable
Study to assess the effect of an added Synbiotic mixture on Atopic dermatitis in INfanTs.Atopic Dermatitis
NL-OMON23678This clinical study will be performed within TOP Institute Pharma (project T1-501). Besides Danone Research, also the Academic Medical Center (AMC) Amsterdam, Wilhelmina Children's Hospital (WKZ) Utrecht, VU University Amsterdam, and the Utrecht Institute for Pharmaceutical Sciences (UIPS) will participate in the TOP Institute Pharma project. Danone Research shall take care of the Sponsor responsibilities as defined by ICH-GCP'.144